Multiple sclerosis trials in Netherlands

In Netherlands 17 Also abroad 506

17 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Where
Geleen
Age
18 years to 60 years
People
705 worldwide
Run by
Zenas BioPharma (USA), LLC
See details and how to joinNCT07067463 · EU 2025-524316-11-00
Phase 3Taking people
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Where
Dordrecht, Geleen
Age
18 years to 60 years
People
990 worldwide
Run by
Zenas BioPharma (USA), LLC
See details and how to joinNCT07299019 · EU 2025-524322-18-00
Phase 3Taking people
Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis
Where
Heerlen
Age
18 years to 64 years
People
386 worldwide
Run by
Sanofi-Aventis Recherche & Developpement
See details and how to join2023-504358-36-00 · EU 2023-504358-36-00
Phase 2Taking people
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis
Where
Amsterdam, Leiden
Age
18 years to 64 years
People
230 worldwide
Run by
Immunic AG
See details and how to joinNCT05054140 · EU 2024-514617-35-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Where
Amsterdam, Arnhem, Leiden, 's-Hertogenbosch, Sittard-Geleen
Age
18 years to 65 years
People
1,275 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07225504
Phase 3Taking people
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Where
Rotterdam
Age
18 years to 60 years
People
160 worldwide
Run by
Sanofi
See details and how to joinNCT07325292 · EU 2026-525688-41-00
Phase 2Taking people
A trial to assess the efficacy and safety of ACT-1004-1239 in adults with progressive multiple sclerosis
Where
Leiden
Age
18 years to 64 years
People
32
Run by
Idorsia Pharmaceuticals Ltd.
See details and how to join2025-522922-11-00 · EU 2025-522922-11-00
Phase 3Taking people
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
Where
Amsterdam, Arnhem, Geleen, Leiderdorp, 'S-Hertogenbosch
Age
18 years and over
People
677 worldwide
Run by
Novartis Pharma AG
See details and how to join2025-521546-23-00 · EU 2025-521546-23-00
Phase 2Taking people
Use of Indipamide to reduce progression of disability in people with primary and secondary progressive multiple sclerosis (MS).
Where
Amsterdam
Age
18 years to 64 years
People
84
Run by
Amsterdam UMC Stichting
See details and how to join2026-525260-18-00 · EU 2026-525260-18-00
Phase 2Taking people
Psilocybin Therapy for Psychological Distress in Palliative Patients
Where
Groningen
Age
18 years and over
People
108 worldwide
Run by
University Medical Center Groningen
See details and how to joinNCT06782724 · EU 2023-510488-36-01
No phaseTaking people
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
Where
Leiden
Age
18 years to 65 years
People
126 worldwide
Run by
Universiteit Leiden
See details and how to joinNCT07225868
No phaseTaking people
Don't be Late! Postponing Cognitive Decline and Preventing Early Unemployment in People With Multiple Sclerosis
Where
Amsterdam
Age
18 years to 67 years
People
270
Run by
Amsterdam UMC, location VUmc
See details and how to joinNCT06068582
No phaseTaking people
The MS-CEBA Study: Determining Cognitive, Energetic, Behavioural and Affective (CEBA) Profiles in Multiple Sclerosis
Where
Groningen
Age
18 years to 70 years
People
500
Run by
University Medical Center Groningen
See details and how to joinNCT06016309
No phaseTaking people
Spinal Cord Monitoring in Multiple Sclerosis
Where
Arnhem, Dordrecht, Geleen, Rotterdam, 's-Hertogenbosch
Age
18 years to 65 years
People
155
Run by
Zuyderland Medisch Centrum
See details and how to joinNCT06827834
No phaseNot yet taking people in Netherlands
Validating Digital Biomarkers to Detect Disease Activity and Disease Progression in Multiple Sclerosis
Where
Amsterdam, Arnhem, Geleen
Age
18 years and over
People
600
Run by
Amsterdam UMC, location VUmc
See details and how to joinNCT06627465
No phaseTaking people
Multiple Sclerosis Treatment With Autologous Hematopoietic Stem Cell Transplantation in the Netherlands
Where
Amsterdam, Nieuwegein
Age
18 years to 65 years
People
24
Run by
Amsterdam UMC, location VUmc
See details and how to joinNCT06567197
Phase 3Taking people
Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS
Where
Amsterdam
Age
18 years and over
People
200
Run by
Amsterdam UMC, location VUmc
See details and how to joinNCT05834855